Chapter Two
Systematic Fixed Income Strategies and Market Challenges
Systematic strategies are having a real impact on the industry.
Rather than replacing traditional approaches, they are automating them, enabling firms to process increasingly complex datasets at speed while still relying on human expertise to interpret and act on those insights.
Evidently, leaders are adopting systematic strategies in practice, revealing a market evolving toward a hybrid model in which technology enhances decision-making but does not replace it.
Leaders were asked to describe the role that systematic strategies play in their fixed income investment processes, and they highlighted that systematic approaches provide a clear edge in processing large, complex datasets and uncovering opportunities not visible through traditional analysis.
At the same time, firms emphasise that human judgment remains key to ensure insights are applied appropriately within broader investment strategies.
Q: Select one statement from each of the following categories that best reflects your view of Fixed Income market transparency and one primary challenge.
A. Transparency
B. Pricing Challenge
However, this evolution is taking place within a market that is still far from fully transparent. While 58% of respondents describe fixed-income markets as moderately transparent, 32% still see them as fragmented, and only 10% consider them highly transparent.
This fragmentation is most evident in the area that firms find hardest to price.
Private credit emerges as the single biggest pricing challenge (32%), followed by cross-asset correlations (27%), reinforcing the idea that complexity and opacity remain concentrated in specific market segments.
At the same time, firms are clear on what data matters most to improving pricing models, with trade prints (63%) and dealer quotes (56%) identified as the most critical inputs.
Q: Where do you see the most pricing inefficiency across the credit complex? (Respondents were asked to select one options)
The message is clear. While some operational variability is recognised as inevitable, tolerance for failure during launch remains extremely low.
This is where the industry’s vulnerabilities become most visible. Pharmaceutical supply chains operate in an environment of increasing volatility, yet during their most critical moments — new product launches — the margin for error approaches zero.
Designing networks that can meet that standard, without escalating cost indefinitely, represents one of the sector’s central strategic challenges.




